Clinical trials: Metformin, completed
Type 2 Diabetes
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin…
- Trial name
- NCT07076056
- Testing
- DW1026C1, DW1026C2, DW1026S
- Where
- South Korea
- Volunteers
- 230 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Iatrogenic Cushing Disease
Prevention of Metabolic Complications of Glucocorticoid Excess
According to current estimates, nearly 1% of the general population is treated with long-term glucocorticoids. Chronic hypercortisolism leads to a phenotype that resembles the metabolic syndrome.
- Trial name
- NCT01319994
- Testing
- Metformin
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Barts & The London NHS Trust
Diabetes Mellitus, Type 2, Coronary Artery Disease
Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery
Background Endothelial dysfunction is one of the early events in atherosclerotic plaque development. It is characterized by an increased ratio of substances with vasoconstrictive, pro-thrombotic, and proliferative properties over…
- Conditions
- Diabetes Mellitus, Type 2, Coronary Artery Disease, Carotid Artery Diseases
- Trial name
- ADDENDA (NCT02919345)
- Testing
- Dapagliflozin 10 mg, Glibenclamide 5 mg
- Where
- Brazil
- Volunteers
- 98 people
- Sponsor
- University of Campinas, Brazil
Type 2 Diabetes Mellitus
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
Primary objective: The primary objective of this study is to define the dose response of Glymera as measured as the change from baseline in hemoglobin A1c (HbA1c) following 20 weeks of once-weekly dosing.
- Trial name
- NCT01658501
- Testing
- 50 mg PB1023, 70 mg PB1023, 100 mg PB1023
- Where
- 93 sites in United States
- Volunteers
- 593 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Healthy
Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers
Study to demonstrate bioequivalence of a 2.5 mg linagliptin/1000 mg metformin fixed-dose combination (FDC) tablet compared with single tablets of linagliptin 2.5 mg and metformin 1000 mg administered together.
- Trial name
- NCT02221401
- Testing
- Linagliptin/Metformin FDC, Linagliptin, Metformin
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Safety and Efficacy of Albiglutide in Type 2 Diabetes
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
- Trial name
- NCT00849056
- Testing
- albiglutide
- Where
- 331 sites in United States, India and 4 more
- Volunteers
- 310 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Non-Insulin-Dependent
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug…
- Trial name
- NCT01105429
- Testing
- BMS-820132
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb
Obesity, Type 2 Diabetes Mellitus
Metformin in Overweight Type 2 Diabetes Mellitus
The study included 102 overweight type 2 diabetes mellitus patients with a body mass index (BMI) of more than 25 in an open label study.
- Trial name
- NCT00922194
- Testing
- Extended Release Metformin
- Where
- India
- Volunteers
- 102 people
- Sponsor
- Era's Lucknow Medical College
Healthy
A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers
The purpose of this study is to evaluate the bioequivalence of a fixed dose combination (FDC) tablet of canagliflozin and metformin immediate release (IR) in comparison with the individual components of canagliflozin and…
- Trial name
- NCT01463228
- Testing
- A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Ischemia Reperfusion Injury, Endothelial Function
The Metformin-FMD Trial
In acute myocardial infarction early restoration of coronary blood flow is the most effective strategy to limit infarct-size. Paradoxically, reperfusion itself also aggravates myocardial injury and contributes to final infarct…
- Trial name
- MetFMD (NCT01610401)
- Testing
- Metformin, Pretreatment with metformin in combination of infusion of caffeine., No pretreatment with metformin in combination with infusion of caffeine
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Low Milk Supply, Pre-diabetes
Metformin to Augment Low Milk Supply (MALMS) Study
Most new mothers in the United States will start off breastfeeding. For some mothers, despite following best practices, they are not able to meet their breastfeeding goals due to unexplained low milk supply.
- Conditions
- Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
- Trial name
- MALMS (NCT02179788)
- Testing
- Standard care, Metformin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
PCO
Dapagliflozin Versus Metformin and Their Combination in Polycystic Ovary Syndrome
The aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and dapagliflozin as monotherapies and the effect of both of them as a combined therapy in women with PCOs.
- Trial name
- NCT05601336
- Testing
- Dapagliflozin 5 MG, Metformin Hydrochloride 1000 MG, Dapagliflozin/Metformin
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Beni-Suef University
NAFLD (Nonalcoholic Fatty Liver Disease)
A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.
The goal of this clinical trial is to learn if drugs Dapagliflozin and Empagliflozin work to treat NAFLD in Type 2 diabetes patients. It will also learn about the safety of drugs dapagliflozin and empagliflozin.
- Trial name
- (Dapa)& (Empa) (NCT07363707)
- Testing
- Dapagliflozin + Metformin, Empa
- Where
- Egypt
- Volunteers
- 108 people
- Sponsor
- Beni-Suef University
Type 2 Diabetes
The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients
This study aims to confirm that SHR20004 is more effective than placebo in controlling blood glucose in patients with type 2 diabetes. Evaluate the efficacy, safety, and pharmacokinetics of SHR20004 after 24 weeks of treatment.
- Trial name
- NCT06649773
- Testing
- Noiiglutide Injection
- Where
- China
- Volunteers
- 137 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus
Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus
The goal of this clinical trial is to compare the effects of Sitagliptin and Empagliflozin in combination with metformin on High sensitivity C reactive proteins (hs-CRP) levels and efficacy in T2DM patients.
- Trial name
- NCT06952231
- Testing
- Sitagliptin + Metformin, Empagliflozin + Metformin
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- University of Lahore
Diabetes, Diabetes Mellitus, Type 2
Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect and the safety profile of biphasic insulin aspart 30 compared to biphasic human insulin 30, both in combination…
- Trial name
- NCT00807092
- Testing
- biphasic insulin aspart 30, biphasic human insulin 30, metformin
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Drug to Drug Interaction Study With ASP1941 and Metformin
A study to investigate the effect on safety, pharmacokinetics and pharmacodynamics when ASP1941 is administered as add-on therapy to metformin.
- Trial name
- NCT01302145
- Testing
- ASP1941, Metformin
- Where
- 5 sites in Hungary, Netherlands and 2 more
- Volunteers
- 36 people
- Sponsor
- Astellas Pharma Inc
Metabolic Syndrome, HIV Seropositivity
A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.
Metabolic syndrome is a constellation of risk factors for cardiovascular disease and type 2 diabetes mellitus which frequently occur together.
- Trial name
- SMART (NCT05571319)
- Testing
- Metformin Extended Release Oral Tablet
- Where
- South Africa
- Volunteers
- 30 people
- Sponsor
- University of Stellenbosch
Type 2 Diabetes Mellitus
Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)
The incidence of type 2 diabetes is on the increase. According to recent Canadian Diabetes Association guidelines glucose control, based on the A1C measurement, needs to be achieved within a 6-12 month period of time after the…
- Trial name
- AVALANCHE (NCT00131664)
- Testing
- Avandamet, Avandia and Amaryl, Metformin
- Where
- Canada
- Volunteers
- 391 people
- Sponsor
- Canadian Heart Research Centre
Type 2 Diabetes
Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients
This is a multicentre, non-interventional, prospective, observational study which would be conducted in India to understand the usage and effect of saxagliptin as first add-on therapy after metformin.
- Trial name
- ONTARGET-INDIA (NCT02588859)
- Where
- 31 sites in India
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.